Militia Capital Partners LP Reduces Stake in Moderna, Inc. $MRNA

Militia Capital Partners LP reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 77.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 13,884 shares of the company’s stock after selling 49,000 shares during the period. Militia Capital Partners LP’s holdings in Moderna were worth $359,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Norges Bank bought a new position in shares of Moderna during the 2nd quarter valued at approximately $94,910,000. Vanguard Group Inc. raised its holdings in Moderna by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after buying an additional 1,312,192 shares during the period. Legal Advantage Investments Inc. bought a new stake in Moderna in the third quarter worth $1,244,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Moderna during the third quarter worth $2,351,000. Finally, Thrivent Financial for Lutherans boosted its stake in Moderna by 600.7% during the second quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company’s stock worth $2,566,000 after buying an additional 79,726 shares during the period. 75.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the topic of several recent analyst reports. The Goldman Sachs Group increased their target price on shares of Moderna from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the company a “hold” rating in a report on Tuesday, March 3rd. Sanford C. Bernstein reissued a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Finally, Morgan Stanley set a $30.00 target price on Moderna in a research note on Monday, February 16th. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $32.33.

Moderna Price Performance

Shares of MRNA stock opened at $53.31 on Tuesday. The company has a market capitalization of $21.05 billion, a P/E ratio of -7.33 and a beta of 1.29. The company’s 50-day simple moving average is $45.97 and its two-hundred day simple moving average is $33.51. Moderna, Inc. has a one year low of $22.28 and a one year high of $59.55. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, beating the consensus estimate of ($2.79) by $0.68. The firm had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company’s revenue was down 33.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.91) earnings per share. As a group, equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the sale, the president directly owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. The trade was a 9.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.90% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.